Evaluating PT027 vs. PT007 for Asthma
Phase 3
440
about 3.4 years
12–17
94 sites in AK, AR, AZ +33
What this study is about
This trial is testing whether a new treatment, PT027, is better than PT007 at preventing severe asthma attacks in children and teens with asthma who have had a severe attack recently. Participants will use the treatments as needed when they feel symptoms of asthma.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use AS MDI
- 2.Use BDA MDI
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
inhaled
Secondary: Apparent total body clearance (CL/F), Maximum Observed Concentration (Cmax), Number of participants with adverse events (AEs) and severe adverse events (SAEs), Terminal elimination half-life (t½λz), Time to first (TTF) severe asthma exacerbation, Time to reach maximum concentration following drug administration (Tmax)
Respiratory